GENEVA, October 25, 2010 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif(R) (interferon beta-1a) significantly delayed conversion to multiple sclerosis (MS) diagnosed according to the McDonald criteria 2 in patients with a first clinical event suggestive of the disease.

The international REFLEX study with 517 patients was conducted with the serum-free formulation of Rebif(R) 3, which was first introduced in 2007 and is now available in all European Union countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East. The serum-free formulation of Rebif(R) is currently not available in the United States.

The risk of conversion to MS (McDonald criteria) over two years was reduced by 51% (p

Serono (NYSE:SRA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Serono
Serono (NYSE:SRA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Serono